Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06480578 · ClinicalTrials.gov registry record · Phase 2
An Integrated Intervention Using a Pill Ingestible Sensor System
A Phase 2 study of HIV/AIDS and Medication Adherence, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT06480578: Recruiting Phase 2 study of HIV/AIDS and Medication Adherence, sponsored by University of California, Los Angeles.
NCT06480578 is a Phase 2 study of HIV/AIDS and Medication Adherence that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 110 participants, below the 33,179-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06480578, a Phase 2 study of HIV/AIDS and Medication Adherence, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
This study integrates technology-based adherence measures with alerts for social and behavioral determinants of health (SBDOH) to improve HIV treatment outcomes. It involves 110 adult patients from a Los Angeles County HIV clinic, focusing on those at risk for poor adherence. Participants will be randomized into intervention or usual care groups, with endpoints including intervention acceptability, SBDOH interventions, adherence to ART, viral load, and high-risk sexual activity. The study aims to assess the effectiveness of the integrated intervention in improving adherence, virologic outcomes, and reducing high-risk behavior among PLWH.
Primary Outcome
Acceptability to the integrated intervention will be evaluated by quantitative measures interviews. The items in the quantitative measure will be rated on five-item Likert scales ranging from very strongly disagree to very strongly agree. Domains to be assessed will include overall satisfaction (would recommend to friend, would use outside of study setting, satisfied with system), utility, and specific items such as helpfulness and convenience. In addition, the investigators will ask participant
Conditions Studied
Interventions
- BEHAVIORAL ISS-SBDOH arm
Study Locations (1)
California
- Lundquist - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
What NCT06480578 shows while recruiting
NCT06480578 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 33,179-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with HIV/AIDS appearing as the primary indexed condition, and to 1 intervention - of which ISS-SBDOH arm is the first listed.
NCT06480578 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06480578 about?
NCT06480578 is a clinical study titled "An Integrated Intervention Using a Pill Ingestible Sensor System". This study integrates technology-based adherence measures with alerts for social and behavioral determinants of health (SBDOH) to improve HIV treatment outcomes. It involves 110 adult patients from a Los Angeles County HIV clinic, focusing on those at risk for poor adherence. Participants will be ra...
What is the current status of trial NCT06480578?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2024-12-19. Estimated completion is 2027-07-01.
What conditions does trial NCT06480578 study?
This clinical trial studies the following conditions: HIV/AIDS, Medication Adherence, Social Determinants of Health (SDOH).
What interventions are being tested in trial NCT06480578?
The interventions under investigation include: ISS-SBDOH arm (BEHAVIORAL).
Who is sponsoring clinical trial NCT06480578?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06480578 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV/AIDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06480578's enrollment target sits among peer trials
110 33rd of 61 higher than 29 of 61 other HIV/AIDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Semaglutide in HIV-Associated Lipohypertrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
RECRUITING · NA
-
MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM
RECRUITING · NA
-
MyPEEPS LITE Trial
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI